Serum Institute To Produce Oxford University Invented Covid-19 Vaccine Doses For Low Income Countries
As the race across nations intensifies to come up with a vaccine to the Covid-19 virus, India is now moving ahead with its plans to give quick approvals to the Serum Institute of India that is now reaching its Phase 3 of vaccine trials.
On trial is the promising Covid-19 vaccine that has been developed by the University of Oxford in the UK. There are already rumours over Kremlin having appointed hackers to have stolen the formula to the vaccine.
Apart from seven other major Indian pharma companies, Serum Institute was also working to develop a successful vaccine against corona virus. As of now,
Serum Institute has entered a manufacturing partnership with AstraZeneca to produce and supply 1 billion doses of the Covid-19 vaccine being developed by Oxford University, as confirmed by the CEO Adar Poonawalla.
Giving out a formal statement via videoconferencing, the Chairperson, National Task Force for Covid-19, Niti Aayog, V.K Paul has confirmed that, “ Serum Institute will get speedy support in the form of expediting processes through the drug controller general office, regulatory assistance, financial assistance if need be.”
Substantiating on the Indian government’s seriousness to come up with a lasting solution to the Covid-19 situation, Rajesh Bhushan, officer on special duty and health secretary-designate, added that a process of accelerated approval of vaccines, drugs and other medical products for covid-19 is already in place, and even foreign developers can use that route. Permission to enter the Phase 3 trials is awaited. As soon as the permission comes in, Serum Institute that has been licensed by AstraZeneca will start production of an additional one billion doses, principally for low- and middle-income countries. Total manufacturing capacity currently stands at two billion doses.